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Abstract
Background: Regulators and clinical experts increasingly recognize the importance of incorporating
patient-reported outcomes (PROs) in clinical studies of therapies for pulmonary arterial hypertension (PAH). No
PAH-specific instruments have been developed to date in accordance with the 2009 FDA guidance for the
development of PROs as endpoints in clinical trials. A qualitative research study was conducted to develop a new
instrument assessing PAH symptoms and their impacts following the FDA PRO guidance.
Methods: A cross-sectional study was conducted at 5 centers in the US in symptomatic PAH patients aged 18–80 years.
Concept elicitation was based on 5 focus group discussions, after which saturation of emergent concepts was reached.
A PRO instrument for PAH symptoms and their impacts was drafted. To assess the appropriateness of items, instructions,
response options, and recall periods, 2 rounds of one-on-one cognitive interviews were conducted, with instrument
revisions following each round. Additional interviews tested the usability of an electronic version (ePRO). PRO
development considered input from an international Steering Committee, and translatability and lexibility assessments.
Results: Focus groups comprised 25 patients (5 per group); 20 additional patients participated in cognitive interviews
(10 per round); and 10 participated in usability interviews. Participants had a mean ± SD age of 53.1 ± 15.8 years, were
predominantly female (93 %), and were diverse in race/ethnicity, WHO functional class (FC I/II: 56 %, III/IV: 44 %), and
PAH etiology (idiopathic: 56 %, familial: 2 %, associated: 42 %). The draft PRO instrument (PAH-SYMPACT®) was found to
be clear, comprehensive, and relevant to PAH patients in cognitive interviews. Items were organized in a draft
conceptual framework with 16 symptom items in 4 domains (respiratory symptoms, tiredness, cardiovascular symptoms,
other symptoms) and 25 impact items in 5 domains (physical activities, daily activities, social impact, cognition,
emotional impact). The recall period is the past 24 h for symptoms, and the past 7 days for impacts.
Conclusions: The PAH-SYMPACT® was shown to capture symptoms and their impacts relevant to PAH patients,
demonstrating content saturation, concept validity, and ePRO usability. Final content and psychometric validation of the
instrument will be based on the results of an ongoing Phase IIIb clinical trial in PAH patients.
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Background
Pulmonary arterial hypertension (PAH) is a rare and de-
bilitating chronic disease of the pulmonary vasculature,
characterized by vascular proliferation and remodeling
of the small pulmonary arteries [1, 2]. If not treated, it
ultimately leads to right heart failure and premature
death [3].
The most recent clinical classification scheme for pul-
monary hypertension (PH) from the 5th World Sympo-
sium on PH distinguishes Group 1 PAH from other
forms of PH (Groups 2–5) [4]. Although all PH Groups
share symptoms in common [5], there may be differ-
ences between types of PH in the relative importance of
symptoms and their impacts on patients [6], and poten-
tially also in the types of symptoms.
The most common symptoms reported by patients
with PAH are shortness of breath with exertion and fa-
tigue [7]. Symptoms of PAH progress in severity if un-
treated [3], and may have a major impact on patients’
functioning and physical, psychological, and social well-
being [8, 9]; higher rates of depression have been found
among PAH patients [10].
Recommendations for PAH trial endpoints from the
4th and 5th World Symposia on PH stress the import-
ance of measuring patient-reported outcomes (PROs) as
a secondary endpoint in clinical trials [11, 12]. These de-
velopments reflect the rising importance accorded to the
patient voice in the drug development and approval
process across diseases [13]. Notably, the US Food and
Drug Administration (FDA) has implemented a new
Patient-Focused Drug Development (PFDD) initiative,
intended to bring patient perspectives into early stages of
product development [14]. As part of the PFDD, the FDA
conducted a public meeting to capture perspectives from
patients living with PAH about their disease, its impact on
their daily life, and currently available therapies [15].
The FDA has established guidance providing clear sci-
entific standards for clinical outcome assessment [16].
The 2009 FDA guidance for PROs defines a PRO assess-
ment as a report of the status of a patient’s health condi-
tion that comes directly from the patient, without
interpretation of the patient’s response by a clinician or
anyone else [17]. The PRO guidance and the FDA’s 2013
roadmap to patient-focused outcome measurement in
clinical trials both emphasize the need to document the
content validity of a PRO in patients with the disease
[17, 18]. Establishing content validity involves docu-
menting that the structure and content (i.e., items) of
the PRO instrument capture the connection between the
intended measurement concept and the way patients
from the target population understand and discuss that
concept [19].
Most PRO questionnaires used in previous PAH clin-
ical trials are generic quality-of-life (QoL) measures that
do not adequately reflect the clinical status and symptoms,
changes in health status and symptoms, or prognosis of
patients with PAH [8, 20]. Other disease-specific PROs
that have been used in PAH were either developed in pa-
tient populations other than PAH, such as the Minnesota
Living with Heart Failure Questionnaire (MLHFQ) [21],
or in mixed samples that included PAH patients and pa-
tients with other forms of PH. Accordingly, there was a
need for a PRO questionnaire developed to assess PAH
symptoms and impacts, which can serve as an efficacy
endpoint in future PAH studies.
Methods
Study design
In accordance with the FDA roadmap to patient-focused
clinical outcome assessment [18], a search was under-
taken for existing questionnaires that would meet the
PRO guidance requirements for use in PAH studies. No
existing PRO measure developed according to the guid-
ance requirements was found, and it was deemed not
feasible to modify existing PRO measures. To develop a
new disease-specific PRO, a multi-center, cross-sectional,
qualitative PRO research study was conducted in patients
with PAH in the US between November 3, 2011 and Janu-
ary 9, 2013. The overall study comprised 3 phases (Fig. 1):
a concept elicitation phase leading to a draft PRO, a sec-
ond phase comprising 2 rounds of cognitive interviews,
and a final cognitive and usability interview phase based
on the electronic version of the instrument (ePRO).
Interviewers used semi-structured interview guides,
and interviews were transcribed by a third-party profes-
sional transcription service.
The study was conducted in consultation with a Steer-
ing Committee (SC) consisting of 3 expert clinicians from
the US, the UK, and Germany, and a research instructor
with a nursing background from the US. The SC provided
clinical expertise and assisted with study design, interpret-
ation of patient responses, item development and item
modification, taking patients’ feedback into account. The
SC also provided guidance on whether elicited symptoms
were generally related to PAH rather than being due to
comorbidities or side effects of treatment. The research
protocol was approved by the institutional review board of
each participating institution (Ethical Review Committee,
Inc., Colorado Multiple Institutional Review Board, Legacy
Health IRB and Intermountain Healthcare IRB). All par-
ticipants provided written informed consent.
Each phase of the study included a translatability as-
sessment to ensure that the items were appropriate and
relevant across cultures, in order to facilitate future
translations of the new PRO instrument. Lexibility as-
sessment using the Flesch-Kincaid Grade Level Scale
(scored to correspond to school grade level) was conducted
after Phases 1 and 3 to ensure that the instructions, items,
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and response options were easy to understand by individ-
uals with a range of reading levels. A 6th to 9th Grade
reading level was considered acceptable, in terms of being
inclusive of patients with lower levels of education [22].
Phase 1
The concept elicitation phase of the study involved discus-
sions in focus groups, each with 5 PAH patients, using
open-ended questions to elicit all concepts regarding PAH
symptoms and their impacts on patients’ lives that were
considered by patients to be relevant and important.
Focus-group discussions were chosen as the appropriate
format for concept elicitation as they allow respondents to
use the ideas of others as cues to express their own views,
and also to compare with their own experiences [19]. In
this phase, potential item recall periods and response scale
options for the questionnaire were also assessed.
The FDA requires evidence that concept saturation has
been reached in the item-generation phase of PRO develop-
ment [17]. In this context, saturation is defined as the point
at which no new relevant or important information emerges
and collecting additional data will not likely add to the
understanding of how patients perceive the symptoms and
impacts of their disease [17]. Accordingly, focus groups in
the present study were continued until the point at which
no substantially new information or concepts continued to
emerge beyond what had been mentioned in previous
focus-group discussions [23]. All concepts were summa-
rized in saturation grids for symptoms and for impacts.
Once saturation was reached for symptoms and im-
pacts, a draft PRO questionnaire was developed following
generally accepted procedures [24], incorporating feed-
back from the SC, translatability assessment, and lexibility
assessment. The saturation grid was used as the basis for
identifying the items to be included in the draft question-
naire. Symptoms due to adverse events were not included,
as the objective was to develop a PRO to serve as an effi-
cacy endpoint in future PAH studies. For symptoms of
PAH, the threshold for including an item was that at least
20 % of the patients in the total sample (i.e., ≥5 patients)
had mentioned it. For impacts, the threshold was emer-
gence of a concept in at least 2 of the 5 focus groups. The
rationale for the different thresholds for including symp-
tom vs. impact items was that symptoms, being typically
expressed in specific terms (e.g., breathlessness), could be
compared across individual patients. In contrast, impacts
were often expressed in general terms (e.g., interference
with daily activities) and individuals varied in how they de-
scribed impacts.
For the draft PRO, a draft conceptual framework was
developed, which is an organizing tool to depict the
relationship of the items to hypothesized domains (i.e.,
categories of items) [19] for both PAH symptoms and
impacts.
Phase 2
The overall objective of Phase 2 was to assess the
appropriateness of several aspects of the draft PRO
Fig. 1 Study flow
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instrument, including confirming that PAH patients
understood its items as intended and that they consid-
ered its items both relevant and comprehensive (i.e., no
new concepts emerged in discussions with patients). In
addition, Phase 2 assessed the appropriateness of the in-
structions, response options, and recall periods for
symptoms and impacts. The formatting of the draft PRO
was also evaluated.
Phase 2 consisted of 2 rounds of semi-structured one-
on-one cognitive interviews with different patients from
those participating in Phase 1, conducted either face-to-
face or by telephone for those patients unable to easily
travel to the study centers. Ten patients were included
in each round of interviews (10 interviews are generally
considered to be sufficient to reach saturation in cogni-
tive interviewing [23]). Inclusion of a second round of
cognitive interviews enabled confirmation of revisions to
the draft PRO implemented after the first round. Ques-
tionnaire revisions followed each interview round, taking
into account patient responses, as well as SC input and
translatability assessment of any changes.
Phase 3
Phase 3 comprised 10 additional face-to-face cognitive
interviews (following the same sample-size consider-
ations as for Phase 2) with different patients from those
participating in Phases 1 and 2, to confirm the content
validity and appropriate patient interpretation of the
PRO following limited changes implemented after Phase
2. Phase 3 also included usability testing by the 10 re-
spondents of an electronic version of the questionnaire
(ePRO) administered on a tablet computer. Prior to
completing the ePRO, participants were provided with
instructions and hands-on training on using the tablet.
Final revisions of the ePRO followed Phase 3, with contin-
ued translatability assessment and lexibility assessment.
Patient population
Patients meeting study eligibility criteria were recruited
from 5 clinical sites in different regions of the US
(Table 1). All participants were required to meet the
following inclusion criteria: age 18–80 years, inclusive;
a definite diagnosis of PAH confirmed by right-heart
catheterization; symptomatic in World Health Organization
(WHO) Functional Class (FC) I–IV as documented
within the past 6 months; and the ability to speak, read,
and understand English.
To exclude patients with other diseases associated
with similar symptoms to those of patients with PAH
and/or patients likely unable to participate in interviews,
patients meeting the following criteria were not eligible
for the study: forms of PH other than PAH; moderate-
to-severe obstructive (forced expiratory volume in 1 s/forced
vital capacity [FEV1/FVC] < 70 %, and FEV1 < 65 % of pre-
dicted value after bronchodilator administration [25]) or
restrictive lung disease (total lung capacity < 60 % of pre-
dicted value [26]) at diagnosis; diagnosis of obstructive
sleep apnea; any other known concomitant life-
threatening disease with a life expectancy <12 months;
any other clinically relevant and/or serious chronic med-
ical condition which, in the opinion of the investigator,
would interfere with the patient’s ability to participate in
an interview; and current participation in a randomized
double-blinded clinical research trial that includes the use
of investigational medications for any condition. Partici-
pants interviewed in one study phase were ineligible for
subsequent study phases.
Recruitment aimed to achieve diversity of patients and
to be generally representative of the PAH population
seen in clinical practice and likely to be recruited in fu-
ture clinical trials (Table 2). The primary source for de-
veloping these recruitment targets was the distribution
of patient characteristics at enrolment in the REVEAL
registry [27, 28]. Diverse disease severity was targeted to
ensure that the PRO would be suitable for use across a
wide range of PAH patients. Patients on oxygen therapy
were intentionally over-recruited to ensure applicability
of the instrument in these patients. Recruitment in
Phase 3 aimed to enroll 50 % of patients aged 65 years
or older, to ensure that the ability of patients in this age
group to use the ePRO could be assessed.
Assessments
To track patients characteristics vs. the recruitment
targets and to characterize patients’ health, assess-
ments administered in each study phase included a
participant-completed sociodemographic form, a clin-
ical questionnaire completed by site clinicians, as well
as 2 numerical rating scales for shortness-of-breath
while walking on a flat surface and climbing up 1 flight of
stairs (0–10; 0 = “No shortness of breath at all”; 10 = “Most
shortness of breath possible”) and the Medical Outcomes
Study 36-item Short Form questionnaire (SF-36, version 2
[29]) which were completed by participants. Participants
in Phase 3 also completed a Device Usability Question-
naire assessing the navigation, readability, screen layout,
font size, ease of use, ease of selecting an answer, and
overall usability of the ePRO.





1 X X X
2 X X
3 X X X
4 X
5 X
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Table 2 Patient demographic and clinical characteristics for targeted recruitment and enrolled cohort









<65 Phase 1 & 2: No exact
target aside from diversity;
Phase 3: 50 %
18 (72 %) 13 (68 %) 8 (80 %) 40 (73 %)
≥65 Phase 1 & 2: No exact
target aside from diversity;
Phase 3: 50 %
7 (18 %) 6 (32 %) 2 (20 %) 15 (27 %)
Mean ± SD 53.6 ± 15.5 54.3 ± 17.7 49.6 ± 13.1 53.1 ± 15.8
Range 28–76 20–79 28–69 20–79
Gender (n, %)
Female 75 %–80 % 23 (92 %) 18 (90 %) 10 (100 %) 51 (93 %)
Male 20 %–25 % 2 (8 %) 2 (10 %) 0 (0 %) 4 (7 %)
Ethnicity (n, %)a
Caucasian 70 %–75 % 17 (68 %) 12 (60 %) 8 (80 %) 37 (68 %)
African American 7 %–10 % 4 (16 %) 4 (20 %) 1 (10 %) 9 (16 %)
Hispanic or Latino 7 %–10 % 1 (4 %) 3 (15 %) 2 (20 %) 6 (11 %)
Asian 3 %–5 % 0 0 0 0
American Indian/Alaskan Native 3 (12 %) 0 (0 %) 0 (0 %) 3 (5 %)
Otherb 0 (0 %) 1 (5 %) 0 (0 %) 1 (2 %)
Highest level of education (n, %) No exact target aside from
diverse educational background
Elementary/primary school 0 (0 %) 0 (0 %) 1 (10 %) 1 (2 %)
Secondary/high school 8 (32 %) 5 (25 %) 1 (10 %) 14 (25 %)
Some college 12 (48 %) 7 (35 %) 6 (60 %) 25 (45 %)
College degree 2 (8 %) 4 (20 %) 1 (10 %) 7 (13 %)
Postgraduate degree 3 (12 %) 3 (15 %) 1 (10 %) 7 (13 %)
Other 0 (0 %) 1 (5 %) 0 (0 %) 1 (2 %)
Incident vs. prevalent patients
Newly diagnosed (incident) 10 %–15 % 2 (8 %) 5 (25 %) 2 (20 %) 9 (16 %)
Previously diagnosed (prevalent) 85 %–90 % 23 (92 %) 15 (75 %) 8 (80 %) 46 (84 %)
Patient’s most recent FC
FC I 5 %–8 % 2 (8 %) 2 (10 %) 0 (0 %) 4 (7 %)
FC II 35 %–40 % 11 (44 %) 8 (40 %) 8 (80 %) 27 (49 %)
FC III 45 %–50 % 11 (44 %) 9 (45 %) 2 (20 %) 22 (40 %)
FC IV 3 %–5 % 1 (4 %) 1 (5 %) 0 (0 %) 2 (4 %)
PAH etiology
APAH 50 %–55 % 11 (56 %) 9 (45 %) 3 (30 %) 23 (42 %)
IPAH 45 %–50 % 14 (44 %) 10 (50 %) 7 (70 %) 31 (56 %)
FPAH 3 %–5 % 0 (0 %) 1 (5 %) 0 (0 %) 1 (2 %)
Shortness of breath at its worst
(numerical rating scale, 0–10), mean ± SD
N/A
Walking on flat surface 4.0 ± 2.2 4.0 ± 2.9 4.8 ± 3.1 4.1 ± 2.7
Climbing up 1 flight of stairs 6.6 ± 2.5 5.3 ± 3.2c 8.1 ± 2.0 6.4 ± 2.9c
aNot mutually exclusive; bParticipant wrote “Jamaican” (n = 1); c1 participant did not answer this question (Phase 2 n = 19, Total n = 54); APAH PAH associated with
other conditions, FC functional class, FPAH familial PAH, IPAH idiopathic PAH, N/A not applicable, PAH pulmonary arterial hypertension, SD standard deviation
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Statistical analysis
Content analyses were performed on the qualitative data
(i.e., the audio recordings and transcripts) from inter-
views. Interviews were analyzed using ATLAS.ti v5.0
qualitative data analysis software (ATLAS.ti Scientific
Software Development GmbH), to assist with the
organization of data and the identification of major con-
cepts. The qualitative data analyses evaluated the satur-
ation of concepts, clarity of instructions, item clarity,
interpretation of items, ease of completion, appropriate-
ness of response options and recall periods, and compre-
hensiveness of the questionnaire (i.e., no missing items).
An item tracking matrix for the PRO was developed to
document the item generation and modification process.
The item tracking matrix included the rationale for deci-
sions to add, drop, retain, or modify items.
Quantitative data analyses were performed to describe
patient demographic and clinical characteristics, as well
as the results of the QoL and numeric rating scale as-
sessments. Summary statistics for the quantitative ana-
lyses are reported as mean and standard deviation (SD)
for continuous variables, and as number and percentage
for categorical variables. SF-36 scores were normalized
to the adult US population [30, 31].
Results
Patient characteristics
A total of 55 patients were enrolled across all 3 study
phases: 25 in Phase 1, 20 in Phase 2, and 10 in Phase 3.
Patients were diverse in key baseline characteristics
(Table 2 and Additional file 1). The overwhelming ma-
jority of patients (84 %) were previously diagnosed (i.e.,
prevalent), and 45 % were using daily oxygen therapy.
Nearly all patients (96 %) were taking at least 1 PAH-
specific medication, and all were taking some medication
to treat PAH (including PAH-specific and nonspecific
medications).
Participants had similar SF-36 scores across study
phases, which revealed poorer health status in all SF-36
domains in comparison with general population norms
in the US, which by definition are 50 for each domain
and summary component score (Fig. 2). The greatest
health impairments were seen in the domains of physical
functioning, role physical, general health, and social
functioning. The importance of shortness of breath in
PAH was confirmed by results of the numerical rating
scales (Table 2).
Phase 1
Concept saturation was reached within 5 focus groups
for all emergently reported PAH symptoms and within 4
focus groups for impacts (i.e., no previously unmen-
tioned symptoms emerged in the fifth focus group and
no new impacts emerged in the fourth and fifth focus
groups). Symptoms reported by participants in all 5
focus groups were: shortness of breath, tiredness/fatigue,
weakness/lack of energy, swelling (in ankles/legs/hands),
rapid heartbeat/heart fluttering, chest pain/tightness,
dizziness/lightheadedness, and fainting/passing out. Com-
mon impacts reported in at least 4 focus groups included:
taking stairs, doing exercise, walking slowly or with diffi-
culty, doing housework, running errands, sleeping difficul-
ties, depression/sadness, frustration/anger, needing help
from others, and effects on work or school.
Fig. 2 SF-36 results (mean ± standard deviation). Dashed line shows the general population norm score (50) for females and males in the US
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The symptoms and impacts selected for inclusion in
the draft PRO are listed in Table 3. To ensure the PRO
reflects symptoms and impacts as experienced by pa-
tients, care was taken to review the comments actually
expressed by the patients in their own words. Examples
of comments spontaneously expressed by patients are
shown in Table 4.
Based on the saturation grid from the focus-group re-
sults and with input from the SC, a draft questionnaire
was developed with 16 symptom and 23 impact ques-
tions. Activities applicable to both genders were selected
for inclusion. Emergent impacts were not included in
the draft questionnaire if they were deemed to be infre-
quently experienced (less than weekly) or unlikely to be
shared by most patients (e.g., pregnancy, sexual rela-
tions), and would therefore likely lead to missing values.
Similar items potentially measuring the same concepts
(e.g., “cough” and “dry cough”) were included in the
draft PRO developed after Phase 1; in Phase 2, patients
were asked whether these items measure the same con-
cept and if yes, which item should be kept.
A standard 5-point Likert response scale was chosen
to assess each item. For symptoms, the response options
were graded in terms of severity (no symptom to very
severe symptom experience). For impacts, response op-
tions were graded either in terms of severity (not at all
to very much) or the level of difficulty associated with
the performance of the activity (none at all to extreme).
Scale selection involved a consideration of both evidence
on performance of different response scales described in
the literature [32] and participant comments during the
interviews: the 0–4 Likert scale with numbers and verbal
anchors is commonly used in research practice for rating
symptoms in pulmonary disorders and has been found
to provide a sufficient range of answer choices to detect
changes in symptom severity [33]. The 5-point Likert
scale was well received by Phase 1 focus-group
participants.
The past 24 h was chosen as an appropriate recall
period for symptoms because some patients reported
their symptoms changed day-to-day. The past 7 days
was chosen as the recall period for impacts because pa-
tients may not have the opportunity to carry out impact
activities on every day of the week. These recall periods
were selected after a review of recall periods that were
identified in the literature as being appropriate for as-
sessment of symptoms and impacts of other chronic and
debilitating diseases [33–35], and with patient confirm-
ation of their appropriateness.
Phase 2
The PRO instrument developed in Phase 1 was named
the Pulmonary Arterial Hypertension-Symptoms and
Impact (PAH-SYMPACT) Questionnaire®. The draft
PAH-SYMPACT® was generally found to be clear, com-
prehensive, and relevant by PAH patients in the Phase 2
cognitive interviews. No additional concepts beyond
those already mentioned in Phase 1 were uncovered in
the new sample of patients interviewed in Phase 2.
In the first round of interviews, all participants (n = 10,
100 %) reported that the symptom questions applied to
their current experiences with PAH and considered the
formatting of the questions appropriate. Nearly all partici-
pants reported that the impact questions applied to their
current experiences (n = 9, 90 %). All of the participants
that were asked said that the symptom instructions were
Table 3 Spontaneously reported PAH symptoms and impacts
selected for inclusion in the draft PRO
n (%)
Symptoms (n = 25 patients)
Shortness of breath 23 (92 %)
Tiredness/fatigue/weakness/lack of energy 21 (84 %)
Swelling in ankles or legs 19 (76 %)
Rapid heartbeat/heart fluttering 19 (76 %)
Chest pain/tightness 16 (64 %)
Dizziness/lightheadedness 14 (56 %)
Cough/dry cough 13 (52 %)
Loss of appetite 10 (40 %)
Swelling in stomach area 6 (24 %)
Impacts (n = 5 focus groups)a
Physical
Stairs/exercise 5 (100 %)
Carrying/lifting things 4 (80 %)
Walking slower or with difficulty 3 (60 %)
Activities of Daily Living
Household chores 5 (100 %)
Errands 5 (100 %)
Work (effects on career or school/reducing hours) 5 (100 %)
Washing/dressing 3 (60 %)
Social Activities
Needing help from others 4 (80 %)
Going out to social activities 3 (60 %)
Maintaining relationships 3 (60 %)






Sad 4 (80 %)
Frustrated/angry/mad 4 (80 %)
Anxious/worried/stressed/loss of control 3 (60 %)
aRefers to difficulties in the listed areas
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clear and easy to understand but some (4/9, 44 %) were
unsure about whether they should answer impact ques-
tions based on whether or not they were using oxygen
during the activity. Modifications made to the draft PAH-
SYMPACT® after round 1 of the cognitive interviews,
following additional input from the translation expert,
included:
 A question about oxygen use was added to allow for
reporting of symptoms and impacts depending on
oxygen use
 One impact question was deleted because
participants said it was not applicable
 One impact question was made more specific to
avoid variability in item interpretation
 The question stem and response options for several
impact items were reworded slightly
No changes were made to the number of symptom
items, symptom question phrasing, instructions, or recall
period.
In the second round of cognitive interviews using the
modified PAH-SYMPACT®, all 10 participants said that
the symptom questions applied to their PAH experience,
considered the general phrasing of the symptom and im-
pact questions to be appropriate, and confirmed that the
instructions were clear and easy to understand. Nine
participants (90 %) considered the impact questions ap-
plied to their experience. Additional modifications after
the round-2 cognitive interviews, made with additional
SC and translation-expert input, included:
 One impact question was added and 1 deleted
 Two impact questions were each separated into 2
distinct questions
 Wording of some impact questions was modified
slightly
The revised PAH-SYMPACT® after Phase 2 comprised
1 question about oxygen use, 16 symptom questions,
and 25 impact questions.
Phase 3
In Phase 3, no participant reported difficulty with any
feature of the tablet device; all had highly positive overall
impressions of using it, and considered it an easy and
convenient way to complete the questionnaire.
Based on participant responses in Phase 3, no relevant
PAH symptoms or impacts were identified as missing.
After patient feedback and input from the translation
expert, the following minor modifications were made:
 One symptom item and 1 impact item were
reworded slightly
 The example given for 1 impact item was changed
to be more relevant
 Some symptom- and impact-item instructions were
modified slightly
The resulting current PAH-SYMPACT® incorporates 4
hypothesized symptom domains comprising 16 items,
and 5 hypothesized impact domains comprising 25 items
(Fig. 3).
Lexibility analysis indicated that the mean ± SD read-
ing grade level is 1.9 ± 1.7 for symptom items and 3.6 ±
2.8 for impact items. The reason for the higher average
reading level for impact items is the need for longer
questions to clarify the intended meaning of some im-
pacts; nevertheless, impact items were easily understood
by patients. For PAH-SYMPACT® instructions, the
Table 4 Example quotations from participants about their PAH symptoms and impacts
Symptom/Impact Example quotation
Shortness of breath I’ve just always had shortness of breath and can hardly breathe sometimes in daily activities …
Tiredness I’m always tired. …Always. I could just get up from a 4-hour nap, and still want to go back to bed because I’m tired.
Swelling in ankles or legs … when I used to have it in my legs and my feet, my legs were so heavy that I could hardly even walk, and my feet were
so swollen.
Rapid heartbeat I’ve had my heart rate go up with just sitting. I’m just sitting there and all of a sudden it starts beating real, real fast, and I
have to take a few deep breaths to try to get it to slow down.
Physical activities You know they say walk-how far can you walk. [laughter] Oh, about two blocks and I have to sit down or something, you know.
Activities of daily living …I’m the cook, and [laughter] used to I’d go in and prepare everything all at one time. Well, now I go in and peel my
potatoes and cut them up and put them on the stove or whatever, and I go back and sit down for 20 minutes, and then I go
back and prepare something else, until finally I have it all going on the stove cooking, but you have to stretch things out.…
Cognition Um, yeah, your thinking sometimes just isn’t—how can I—how can I describe it? You’re not able to think things through
clearly like you had in the past. Um, there’s a hesitation. You know, you might be asked a question, and there’s a
hesitation because you—you’re trying to put the pieces together to respond.
Emotional impacts I mean, I think the biggest impact is just the worry about it, you know. I worry about getting sicker. I worry about what
could happen. You know, I know the stories and how it can go. And you know in the beginning, you read all this stuff,
and you think you’re not going to live a year so you start thinking about that.
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Fig. 3 Conceptual framework
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reading grade level was 11.0 for symptoms and 12.2 for
impacts. The higher scores for instructions are accounted
for by the need to identify the disease by its long and com-
plex name, “pulmonary arterial hypertension”. Instructions
were easily understood by participants since PAH patients
are familiar with the name of their disease and use this
term regularly.
Discussion
The PAH-SYMPACT® questionnaire is the first PRO in-
strument to be developed for PAH by following strictly
the FDA’s PRO guidance. The qualitative research study
described here supports the content validity of the PAH-
SYMPACT® in a general PAH population in the US,
thereby ensuring that the instrument is relevant to
patients.
The PAH-SYMPACT® is designed to be a practical tool
both for use in general practice and in future trials to
assess the effect of PAH and PAH-specific therapies on
patients’ symptoms and their impacts. To ensure the po-
tential for its use as an efficacy endpoint in future PAH
clinical trials, the PAH-SYMPACT® development process
was rigorous with respect to the requirements of the
FDA guidance [17]. A stepwise approach was followed,
starting with a literature review to confirm the need for
a new disease-specific PRO. Patient interviews were con-
ducted in participants representative of both the broader
PAH population and the intended population in PAH
clinical trials, with recruitment targets being generally
met. Patient responses were used as the basis for the de-
velopment of all questionnaire items, with expert clin-
ician input regarding interpretation of the elicited PAH
symptoms and their impacts. The draft PRO was tested
with additional PAH patients, whose cognitive interview
transcripts demonstrated that no important items were
missing and that patients understood the questionnaire’s
wording as intended.
Migration of the questionnaire to a tablet device allow-
ing greater convenience in terms of data capture and
improved data quality (e.g., avoidance of missing data,
automatic date and time stamp) is another strength of
the PAH-SYMPACT®. As required by the FDA, a usabil-
ity study was performed to provide evidence of the feasi-
bility of PAH patients using the ePRO.
The input of a translation expert at each step of ques-
tionnaire revision should help to facilitate the adaptation
of the PRO to different languages. Lexibility assessment
results suggest the PAH-SYMPACT® will be understood
even by respondents with relatively basic education.
Interview participants were able to correctly restate the
instructions in their own words, demonstrating that the
questionnaire instructions were well understood.
Previously, only 3 disease-specific PROs have been de-
veloped for patients with PH: the Cambridge Pulmonary
Hypertension Outcome Review (CAMPHOR) [36], the
Living with Pulmonary Hypertension questionnaire
(LPH) [37], and the emPHasis-10 questionnaire [38].
However, none of these instruments meet the strict FDA
PRO guidance criteria for use in PAH patients. The pop-
ulations used to develop the CAMPHOR and the
emPHasis-10 included patients with some other forms
of PH, primarily chronic thromboembolic pulmonary
hypertension, and there is no evidence of any discussion
of differences of item relevancy or interpretation by PH
etiology for either tool [36, 38]. Whether or not the
same QoL measure can be used in patients with differ-
ent forms of PH remains to be determined [20].
In addition, no evidence was reported that a saturation
analysis was conducted for CAMPHOR and emPHasis-
10 to confirm that all concepts important to patients
were captured. Indeed, CAMPHOR is missing concepts
such as dizziness, chest pain and palpitations [36], which
emerged as important concepts during PAH-SYMPACT®
development and which were described by participants
in the 2014 FDA PFDD meeting with PAH patients [15].
The emPHasis-10 was developed primarily as a simple
scoring system for QoL in PH patients intended for use
in clinical practice, not clinical trials, which might
explain why the instrument does not cover the full
spectrum of PAH symptoms [38].
There was also no demonstration that saturation of
symptoms was reached for the LPH, which was an adap-
tation of an existing measure, the MLHFQ, for use in
PAH populations [37]. Although the LPH was developed
based on interviews of PAH patients exclusively, the
process did not incorporate the potential for addition of
new symptoms and impacts beyond those already cov-
ered by the MLHFQ. The main modification was a
revision to the recall period from 4 weeks to 1 week. Al-
though the latter change was described as an important
modification to ensure the instrument met the FDA
preference for “short recall periods” [37], a 1-week recall
period could introduce recall bias and a daily diary is
likely preferable for symptoms, as patients might not be
able to average symptom burden over several days.
While the PAH-SYMPACT® development process
followed the FDA PRO guidance, there are some consid-
erations when judging its applicability to the intended
patient population. No individuals of Asian descent
could be enrolled in the qualitative research, despite ef-
forts to meet the recruitment target for this group.
Nevertheless, the patient sample may still be considered
representative of a clinical-practice population, since the
proportion of Asians among US patients with PAH is
very low [28]. Based on SC input, no racial differences in
symptoms or impacts are anticipated in PAH; thus the
lack of Asians in the study population is not expected to
diminish the applicability of the questionnaire to this
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population. Another consideration is that more women
were enrolled than seen in clinical practice (93 % vs.
80 % in REVEAL [27]), but since only symptoms and
impacts that are generally experienced by both genders
were included in the instrument, this should not have
impacted the development process. Very few patients
with familial PAH (2 %) or in FC IV (4 %) were included,
reflecting the difficulty of recruiting patients from these
uncommon subgroups.
Although the patients participating in the qualitative
interviews were asked about their PAH symptoms and
impacts, it may be difficult for patients to attribute
symptoms and impacts to their disease. For example,
certain PAH-specific therapies are associated with fluid
retention or lightheadedness, both of which are also
symptoms of PAH. To address this issue, instrument de-
velopment incorporated feedback from the SC on
whether symptoms mentioned by patients were generally
PAH-related or potentially side-effects of treatment,
guided by analyses of symptoms reported by patients
receiving and not receiving different PAH-specific
therapies.
Conclusions
The current PAH-SYMPACT® questionnaire was shown
to be a practical and convenient tool for comprehensively
capturing PAH symptoms and their impacts relevant to
patients. Prior to its use in PAH clinical trials or clinical
practice, the PRO needs to undergo final validation steps,
including identification of a scoring algorithm, and quanti-
tative testing to determine the psychometric measurement
properties of the instrument. This final content and
psychometric validation of the PAH-SYMPACT® will
be based on the results of the SYMPHONY trial (Study
AC-055-401; ClinicalTrials.gov No. NCT01841762), an
ongoing Phase IIIb clinical trial in patients with PAH
in the US.
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